Charles Flexner

Affiliations: 
Johns Hopkins University, Baltimore, MD 
Area:
Medicine and Surgery, Epidemiology
Google:
"Charles Flexner"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Delany-Moretlwe S, Flexner C, Bauermeister JA. (2023) Advancing use of long-acting and extended delivery HIV prevention and treatment regimens. Journal of the International Aids Society. e26126
Flexner C. (2022) The future of long-acting agents for preexposure prophylaxis. Current Opinion in Hiv and Aids. 17: 192-198
Flexner CW, Kashuba A. (2022) Editorial: New drugs for HIV: quo vadis? Current Opinion in Hiv and Aids. 17: 1-3
Chandiwana NC, Serenata CM, Owen A, et al. (2021) Impact of long-acting therapies on the global HIV epidemic. Aids (London, England). 35: S137-S143
Hurwitz SJ, Tao S, Gavegnano C, et al. (2021) Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agents Therapy from the ACTG A5336 Study. Journal of Clinical Pharmacology
Phillips AN, Bansi-Matharu L, Cambiano V, et al. (2021) The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis. The Lancet. Global Health
Marconi VC, Moser C, Gavegnano C, et al. (2021) Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America
Flexner C, Owen A, Siccardi M, et al. (2020) LONG-ACTING DRUGS AND FORMULATIONS FOR THE TREATMENT AND PREVENTION OF HIV. International Journal of Antimicrobial Agents. 106220
Durand CM, Capoferri AA, Redd AD, et al. (2020) Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. The Lancet. Hiv
Rajoli RKR, Demkovich ZR, Flexner C, et al. (2020) Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling. Antimicrobial Agents and Chemotherapy
See more...